RESEARCH ARTICLE


Pharmacokinetic Considerations for Digoxin in Older People



Geoffrey M Currie1, 2, 3, *, Janelle M Wheat1, 2, 3, Hosen Kiat1, 2, 3
1 Faculty of Science, Charles Sturt University, Wagga Wagga, Australia
2 Australian School of Advanced Medicine, Macquarie University, Cardiac Health Institute, Sydney, Australia
3 Centre for Research in Complex Systems, Charles Sturt University, Wagga Wagga, Australia


Article Metrics

CrossRef Citations:
54
Total Statistics:

Full-Text HTML Views: 1829
Abstract HTML Views: 1556
PDF Downloads: 1246
Total Views/Downloads: 4631
Unique Statistics:

Full-Text HTML Views: 916
Abstract HTML Views: 1033
PDF Downloads: 909
Total Views/Downloads: 2858



Creative Commons License
© Currie et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Faculty of Science, Locked Bag 588, Charles Sturt University, Wagga Wagga 2678, Australia; Tel: 61 2 69332822; E-mail: gcurrie@csu.edu.au


Abstract

Objective:

This review aims to arm readers with a deep understanding of pharmacokinetics of digoxin.

Data Sources:

Pharmacology and pharmacokinetic references texts, and peer reviewed medical journal manuscripts indexed on Medline included based on currency, accuracy and appropriateness.

Results:

Results: Physiologic changes and disease associated with aging have an impact on pharmacokinetics and pharmacodynamics of medications. Altered drug response and increased adverse reactions are common amongst the elderly. The narrow therapeutic index of digoxin and pharmacokinetic changes associated with aging increases the risk of toxicity. In the aging population, a number of factors combine to increase the risk, severity and likelihood of hospitalisation or death due to adverse drug effects:

  • changes to absorption, distribution, metabolism and excretion,
  • increased susceptibility to drug sensitivity,
  • co-existing pathology,
  • polypharmacy.

Conclusion:

A thorough understanding of digoxin pharmacokinetics in the older person is essential for improved therapeutic outcomes, improved compliance, reduced morbidity and improved quality of life.

Keywords: Ageing, digoxin, pharmacokinetics, toxicity..